Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Vaccinex Inc (VCNX)

Vaccinex Inc (VCNX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,610
  • Shares Outstanding, K 892
  • Annual Sales, $ 280 K
  • Annual Income, $ -19,820 K
  • 60-Month Beta 0.76
  • Price/Sales 3.20
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade VCNX with:

Options Overview Details

View History
  • Implied Volatility 0.00% ( unch)
  • Historical Volatility 106.38%
  • IV Percentile 0%
  • IV Rank N/A
  • IV High 0.00% on N/A
  • IV Low 0.00% on N/A
  • Put/Call Vol Ratio N/A
  • Today's Volume N/A
  • Volume Avg (30-Day) N/A
  • Put/Call OI Ratio N/A
  • Today's Open Interest N/A
  • Open Int (30-Day) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.29 +1.65%
on 03/28/24
9.34 -20.66%
on 03/12/24
-1.35 (-15.41%)
since 02/28/24
3-Month
7.28 +1.73%
on 01/19/24
13.02 -43.09%
on 02/15/24
-1.84 (-19.87%)
since 12/28/23
52-Week
7.16 +3.48%
on 12/14/23
100.80 -92.65%
on 06/09/23
-74.49 (-90.95%)
since 03/28/23

Most Recent Stories

More News
MarketBeat Week in Review – 2/6 - 2/10

Markets are closed the week looking for direction as investors believe a soft landing is not possible and higher interest rates are likely

AI : 27.07 (-0.70%)
BBAI : 2.05 (-4.65%)
PLTR : 23.01 (-6.12%)
SOUN : 5.89 (-0.67%)
MSFT : 420.72 (-0.17%)
ON : 73.55 (-2.72%)
AAPL : 171.48 (-1.06%)
AMZN : 180.38 (+0.31%)
TTWO : 148.49 (+1.07%)
MRK : 131.95 (+0.15%)
VCNX : 7.41 (-0.54%)
ENPH : 120.98 (+0.98%)
Should Investors Buy or Sell the Vaccinex Patent News?

Shares of Vaccinex, Inc. are higher on February 7 on news that the clinical-stage biotechnology company secured a patent. Is it time to buy or sell the news?

VCNX : 7.41 (-0.54%)
MRK : 131.95 (+0.15%)
Vaccinex, Inc.’s Phase 2 “SIGNAL” Study to Evaluate Pepinemab Antibody in Huntington’s Disease is Published in Nature Medicine along with Detailed Mechanism of Action Study in Journal of Neuroinflammation

Data suggest that pepinemab slows or prevents cognitive decline in Huntington’s Disease (HD) Results highlight the potential for impact on other...

VCNX : 7.41 (-0.54%)
Vaccinex, Inc. Announces Presentation at the 2022 Alzheimer’s Association International Conference Updating the SIGNAL-AD Study of Pepinemab in Patients with Alzheimer’s Disease

ROCHESTER, N.Y., July 29, 2022 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated...

VCNX : 7.41 (-0.54%)
Vaccinex Reports First Quarter 2022 Results and Provides Corporate Update

Excellent Progress in Pepinemab Clinical Programs Promising responses in Phase 1b segment of the open-label KEYNOTE B84 study of pepinemab with KEYTRUDA®...

VCNX : 7.41 (-0.54%)
Vaccinex Reports 2021 Financial Results and Provides Corporate Update

Promising responses in Phase 1b segment of the open-label KEYNOTE B84 study of pepinemab with KEYTRUDA® in Recurrent/Metastatic Head and Neck Squamous Cell...

VCNX : 7.41 (-0.54%)
Vaccinex, Inc. Announces Upcoming Presentation at the 2022 American Association for Cancer Research Meeting Updating the Phase 1b Segment of the KEYNOTE-B84 Study of Pepinemab in Combination with KEYTRUDA (pembrolizumab) in Patients with Recurrent or

ROCHESTER, N.Y., March 09, 2022 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated...

VCNX : 7.41 (-0.54%)
Vaccinex, Inc. to Present at CHDI’s 17th Annual HD Therapeutics Conference Meeting

Poster Presentation: Combination immunotherapy and HTT-lowering in humanized HD mice, Wednesday, March 2, 2022...

VCNX : 7.41 (-0.54%)
Vaccinex Announces $6.6 Million Private Placement

Participants include a syndicate of existing and new shareholdersContributes to total of $10.1 million in new equity financing for January, 2022 ...

VCNX : 7.41 (-0.54%)
R&D Spending Increases Exponentially for Higher Standard of Breast Cancer Drug Treatments

Palm Beach, FL – January 27, 2022 – FinancialNewsMedia.com News Commentary – According to International Agency for Research on Cancer (IARC) published by the World Health Organization (WHO) in 2018,...

PFE : 27.75 (-0.11%)
MRK : 131.95 (+0.15%)
ONCY : 1.0600 (+2.91%)
ONC.TO : 1.45 (+5.07%)
SRRA : 54.99 (+0.04%)
VCNX : 7.41 (-0.54%)
BMY : 54.23 (+1.84%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Vaccinex, Inc. is a clinical-stage immunotherapy company. It engages in the discovery and development of biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases and autoimmune disorders. The company's product pipeline consists of...

See More

Key Turning Points

3rd Resistance Point 8.74
2nd Resistance Point 8.42
1st Resistance Point 7.92
Last Price 7.41
1st Support Level 7.10
2nd Support Level 6.78
3rd Support Level 6.28

See More

52-Week High 100.80
Fibonacci 61.8% 65.03
Fibonacci 50% 53.98
Fibonacci 38.2% 42.93
Last Price 7.41
52-Week Low 7.16

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar